Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP4F2 | P78329 | 2/20 | 0.39 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.37 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.35 |
| ▸ | EP300 | Q09472 | 6/20 | 0.35 |
| ▸ | PDE4D | Q08499 | 2/20 | 0.34 |
| ▸ | AMPD2 | Q01433 | 2/20 | 0.33 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.33 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.33 |
| ▸ | TNF | P01375 | 2/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5111772 | 0.84 | CYP4F2 (0.48) | CYP4F2CYP4A11LMNACYP1A2CYP3A4 | |
| SCHEMBL5381156 | 0.73 | CYP4F2 (0.44) | CYP4F2CYP4A11LMNAEP300L3MBTL1 | |
| SCHEMBL6034566 | 0.72 | TP53 (0.41) | CYP4F2CYP4A11LMNACYP1A2CYP3A4 | |
| SCHEMBL5380841 | 0.71 | KMT2A (0.46) | LMNASMN1; SMN2 | |
| SCHEMBL6036366 | 0.71 | CYP4F2 (0.49) | CYP4F2CYP4A11LMNACYP1A2CYP3A4 | |
| SCHEMBL5107205 | 0.69 | LMNA (0.44) | CYP4F2CYP4A11LMNACYP1A2CYP3A4 | |
| SCHEMBL6035823 | 0.68 | CYP4F2 (0.50) | CYP4F2CYP4A11LMNACYP1A2CYP3A4 | |
| SCHEMBL5377312 | 0.67 | KDM4E (0.47) | CYP1A2CYP3A4CYP2D6CYP2C9CYP2C19 | |
| SCHEMBL5374629 | 0.67 | PPARG (0.46) | CYP4F2CYP4A11LMNAL3MBTL1 | |
| SCHEMBL5392348 | 0.66 | CYP4F2 (0.48) | CYP4F2CYP4A11LMNACYP1A2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2006-07-06 | — | — | US | disclosed |
| EP-1513817-A1 | 1, 2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | Takeda Pharmaceutical Company Limited (JP) | 2005-03-16 | — | — | EP | disclosed |
| WO-2003099793-A9 | 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA PHARMACEUTICAL (JP) | 2005-02-10 | — | — | WO | disclosed |
| WO-2003099793-A1 | 1,2-AZOLE DERIVATIVES WITH HYPOGLYCEMIC AND HYPOLIPIDEMIC ACTIVITY | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2003-12-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060148858-A1 | 1, 2-Azole derivatives with hypoglycemic and hypolipidemic activity | GPR119, SLC5A1, CYP4B1 | CYP4F2 90/4885CYP4A11 18/4885LMNA 1816/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.